The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies
Watch our on-demand Webinar
If you’re evaluating a move from traditional plasmid DNA to synthetic, cell-free DNA, this on-demand webinar provides practical clarity on the scientific, regulatory, and manufacturing considerations.
Hosted by Amy Walker, Ph.D., CEO of 4basebio, with guest expert Jenny Mellquist, Ph.D., the session explores how organisations are addressing pDNA bottlenecks while improving quality, scalability, and patient safety.
You’ll learn:
• Regulatory and CMC expectations when changing a core starting material
• Practical data and requirements for implementation in a cGMP environment
• Technical advantages of synthetic, cell-free DNA